CAR T-Cell Therapy Market to Register Stunning Growth During the Study Period (2019-2032) | DelveInsight

The CAR-T cell therapy market is expected to grow significantly in the coming years, driven by the increasing incidence of cancer and the growing demand for personalized cancer treatments. The market offers several opportunities for growth, including the development of novel CAR-T cell therapies, the expansion of the therapy to other types of cancer, and the increasing adoption of CAR-T cell therapy in emerging markets.

LAS VEGAS, Jan. 23, 2024 /PRNewswire/ -- DelveInsight's CAR T-Cell Therapy Market Insights report includes a comprehensive understanding of current treatment practices, emerging CAR T-cell therapies, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Takeaways from the CAR T-Cell Therapy Market Report

• According to DelveInsight's analysis, the market size for CAR T-cell therapy across the 7MM is expected to grow with a significant CAGR by 2032.
• Leading CAR T-cell therapy companies such as CytoAgents, Inc., Genentech, Inc., Incyte Corporation, Caribou Biosciences, Inc., Chimeric Therapeutics, Allogene Therapeutics, Kyverna Therapeutics, iCell Gene Therapeutics, Synthekine, Janssen Research & Development, LLC, SecuraBio, ImmPACT Bio, A2 Biotherapeutics Inc., Gracell Biopharmaceuticals, Inc., Wugen, Inc., Sana Biotechnology, Oncternal Therapeutics, Inc, Vor Biopharma, CARsgen Therapeutics Co., Ltd., Autolus Limited, Arcellx, Inc., Kite, Novartis, Lyell Immunopharma, Inc., ImmPACT Bio, Tmunity Therapeutics, Poseida Therapeutics, Inc., Precigen, Inc, AffyImmune Therapeutics, Inc., 2seventy bio, Takeda, Cartesian Therapeutics, Cabaletta Bio, Legend Biotech USA Inc, Miltenyi Biomedicine GmbH, Beam Therapeutics Inc., and others are developing novel CAR T-cell therapies that can be available in the CAR T-cell therapy market in the coming years.
• The promising CAR T-cell therapies in the pipeline include CTO1681 10, Cevostamab, Itacitinib, CB-012, CHM-1101, ALLO-605, KYV-101, CD4CAR, SYNCAR-001, JNJ-90009530, Duvelisib, IMPT-514, A2B694, GC012F, WU-CART-007, SC291, ONCT-808, VCAR33, CT041, AUTO1, CART-ddBCMA, PHE885, LYL797, IMPT-314, GPC2, P-MUC1C-ALLO1, PRGN-3005 UltraCAR-T cells, AIC100, SC-DARIC33, TAK-981, Descartes 08, DSG3-CAART, LB1908, MB-CART2019.1, BEAM-201, and others.
• Among all the CAR-T therapies used in the treatment of DLBCL, YESCARTA demonstrated excellent results. Therefore, it will be interesting to know the highest peak share generator in other CAR-T-cell therapies, including KYMRIAH and BREYANZI. Currently, YESCARTA captured the highest patient share among all CAR-T therapies.
• Clinical studies have shown that CAR-T therapy can achieve high response rates, with some studies reporting response rates of up to 80% in patients with multiple myeloma. CAR-T therapy has the potential to induce long-term remission in some patients with multiple myeloma, which may translate into improved overall survival.
• CAR-T therapy holds great promise for the treatment of MCL, and ongoing clinical studies are exploring its potential in this patient population. However, more research is needed to fully understand its long-term safety and efficacy.

Discover which therapies are expected to grab the major CAR T-cell therapy market share @ CAR T-Cell Therapy Market Report

CAR T-Cell Therapy Overview

CAR T-cells are formed by merging a chosen single-chain variable fragment from a particular monoclonal antibody with one or more intracellular signaling domains of T-cell receptors. Essentially, a CAR integrates antigen-binding elements, typically a single-chain variable fragment (scFv) sourced from antibody variable domains, with signaling domains from the TCR chain and supplementary costimulatory domains derived from receptors like CD28, OX40, and CD137.

From the inception of CARs in 1989, CAR T-cells have undergone categorization into four generations based on their intracellular domain structure. The first generation involved the incorporation of the ζ (zeta) chain from the complex TCR/CD3 (CD3ζ). Second-generation CARs are distinguished by a dual signaling mechanism for T-cell activation. This involves triggering one signal through antigen recognition and another through a co-stimulatory molecule, like CD28/B7, which facilitates IL-2 synthesis to ensure full T-cell activation and prevent apoptosis.

CAR T-Cell Therapy Epidemiology Segmentation

The CAR T-cell therapy epidemiology section provides insights into the historical and current CAR T-cell therapy patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.

The CAR T-cell therapy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Incident Cases of Selected Cancer Indications
• Line-wise Treated Cases of Selected Cancer Indications

CAR T-Cell Therapy Treatment Market 

CAR T-cell therapy has undergone swift advancements in cancer treatment, with the US FDA approving six therapies since 2017. These treatments are authorized for addressing blood cancers such as lymphomas, certain types of leukemia, and, most recently, multiple myeloma. The initial approval, KYMRIAH in August 2017, targeted ALL. Presently, CAR T-cell therapies are tailored to the unique characteristics of each patient. 

YESCARTA (axicabtagene ciloleucel) is a genetically modified autologous T-cell immunotherapy with CD19-directed action. It is designated for the treatment of adult patients experiencing relapsed or refractory large B-cell lymphoma after undergoing two or more rounds of systemic therapy. This includes diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL originating from follicular lymphoma. The FDA initially approved YESCARTA on October 18, 2017, followed by approval from the EMA on August 23, 2018.

Following the YESCARTA approval in DLBCL in 2017, the US FDA authorized KYMRIAH (tisagenlecleucel) in May 2018 for treating adult patients with R/R large B-cell lymphoma who had undergone two or more lines of systemic therapy. This encompassed DLBCL, high-grade B-cell lymphoma, and DLBCL resulting from follicular lymphoma. Subsequently, in February 2021, Bristol Myers Squibb disclosed that the US FDA had endorsed BREYANZI (lisocabtagene maraleucel) for adult patients with R/R large B-cell lymphoma (LBCL). This marked the third CAR T-cell therapy approved for DLBCL.

Since November 2023, only two CAR T-cell therapies have gained approval in the field of multiple myeloma. The first FDA-approved CAR T cell therapy for adult patients with relapsed or refractory multiple myeloma who have undergone at least four prior lines of therapy, involving specific medications, was ABECMA (idecabtagene vicleucel), a joint venture by Bristol Myers Squibb and bluebird bio, sanctioned in 2021. Subsequently, in February 2022, the FDA approved CARVYKTI (ciltacabtagene autoleucel) developed by Janssen/Legend Biotech.

To know more about CAR T-cell therapy, visit @ CAR T-Cell Therapies

Pipeline CAR T-Cell Therapies and Key Companies

• CTO1681 10: CytoAgents, Inc.
• Cevostamab: Genentech, Inc.
• Itacitinib: Incyte Corporation
• CB-012: Caribou Biosciences, Inc.
• CHM-1101: Chimeric Therapeutics
• ALLO-605: Allogene Therapeutics
• KYV-101: Kyverna Therapeutics
• CD4CAR: iCell Gene Therapeutics
• SYNCAR-001: Synthekine
• JNJ-90009530: Janssen Research & Development, LLC
• Duvelisib: SecuraBio
• IMPT-514: ImmPACT Bio
• A2B694: A2 Biotherapeutics Inc.
• GC012F: Gracell Biopharmaceuticals, Inc.
• WU-CART-007: Wugen, Inc.
• SC291: Sana Biotechnology
• ONCT-808: Oncternal Therapeutics, Inc
• VCAR33: Vor Biopharma
• CT041: CARsgen Therapeutics Co., Ltd.
• AUTO1: Autolus Limited
• CART-ddBCMA: Arcellx, Inc./Kite
• PHE885: Novartis
• LYL797: Lyell Immunopharma, Inc.
• IMPT-314: ImmPACT Bio
• GPC2: Tmunity Therapeutics
• P-MUC1C-ALLO1: Poseida Therapeutics, Inc.
• PRGN-3005 UltraCAR-T cells: Precigen, Inc
• AIC100: AffyImmune Therapeutics, Inc.
• SC-DARIC33: 2seventy bio
• TAK-981: Takeda
• Descartes 08: Cartesian Therapeutics
• DSG3-CAART: Cabaletta Bio
• LB1908: Legend Biotech USA Inc
• MB-CART2019.1: Miltenyi Biomedicine GmbH
• BEAM-201: Beam Therapeutics Inc.

Learn more about the FDA-approved CAR T-cell therapies @ CAR T-Cell Therapy Treatment Drugs

CAR T-Cell Therapy Market Dynamics

The dynamics of the CAR T-cell therapy market are expected to change in the coming years. CAR-T therapy holds great promise for treating various types of cancer, as ongoing clinical studies investigate its potential. Numerous companies are actively developing allogeneic CAR-Ts and bi-specific CAR-Ts specifically for DLBCL, multiple myeloma, and other forms of cancer.

Furthermore, many potential therapies are being investigated for the treatment of various cancers, and it is safe to predict that the treatment space will significantly impact the CAR T-cell therapy market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the CAR T-cell therapy market in the 7MM.

However several factors may impede the growth of the CAR T-cell therapy market. The growth of the CAR T-cell therapy medicine market has been impeded due to a shortage of trained professionals to administer the treatment in certain developing and underdeveloped countries. Additionally, the high cost of the therapy has also acted as a hindrance to the CAR T-cell therapy market's expansion.

Moreover, CAR T-cell therapy treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the CAR T-cell therapy market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the CAR T-cell therapy market growth.

Scope of the CAR T-Cell Therapy Market Report

• Therapeutic Assessment: CAR T-Cell Therapy current marketed and emerging therapies
• CAR T-Cell Therapy Market Dynamics: Key Market Forecast Assumptions of Emerging CAR T-Cell Therapy Drugs and Market Outlook
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, CAR T-Cell Therapy Market Access and Reimbursement

Discover more about CAR T-cell therapy drugs in development @ CAR T-Cell Therapy Clinical Trials

Table of Contents

Related Reports

CAR T-Cell Therapy Competitive Landscape

CAR T-cell Therapy Competitive Landscape – 2023 report provides comprehensive insights about the pipeline and current landscape, pipeline and marketed drug profiles, and the key CAR T-cell therapy companies, including Alnylam Pharmaceuticals, JW Therapeutics, Gilead Sciences, Janssen Pharmaceuticals, Innovent Biologics, Sorrento Therapeutics, Cartesian Therapeutics, CASI Pharmaceuticals, Juventas Cell Therapy, Novartis, Poseida Therapeutics,Shanghai Unicar-Therapy Bio-medicine Technology, Sinobioway Cell Therapy Co., Ltd., Tessa Therapeutics, Wuhan Bio-Raid Biotechnology, Miltenyi Biomedicine, Bristol-Myers Squibb, Autolus Limited, Beijing Immunochina Medical Science and Technology, Carsgen Therapeutics, Cellular Biomedicine Group, Chongqing Precision Biotech, Eureka Therapeutics, Formula Pharmaceuticals, Guangzhou Bio-gene Technology, Hebei Senlang Biotechnology, Mustang Bio, MolMed, Aurora BioPharma, Atara Biotherapeutics, Autolus, Bellicum Pharmaceuticals, Kecellitics Biotech Company Ltd, Yake Biotechnology, Minerva Biotechnologies, Allogene Therapeutics, PersonGen BioTherapeutics (Suzhou), Precision BioSciences, Pregene (ShenZhen) Biotechnology Company, Shanghai GeneChem, Shanghai Longyao Biotechnology, Shenzhen BinDeBio, among others.

CAR T-Cell Therapy for Multiple Myeloma Market

CAR T-Cell Therapy for Multiple Myeloma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CAR T-cell therapy for multiple myeloma companies, including Cartesian Therapeutics, Arcellx, Novartis, Bristol-Myers Squibb, CARsgen Therapeutics, Poseida Therapeutics, Juno Therapeutics, CRISPR Therapeutics, bluebird bio, Cellectis SA, Caribou Biosciences, Luminary Therapeutics, Celyad Oncology, Allogene Therapeutics, Gadeta, Nanjing IASO Biotherapeutics, among others.

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CAR T-cell therapy for acute lymphoblastic leukemia companies, including Autolus, Pepromene Bio, Actinium Pharmaceuticals, among others.

CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market

CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CAR T-cell therapy for non-Hodgkin's lymphoma companies, including Juno Therapeutics, Allogene Therapeutics, Caribou Biosciences, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur
info@delveinsight.com  
+91-9650213330
www.delveinsight.com 

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg